Quotables
"Man will not fly for 50 years."
Wilbur Wright ; 1901
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7018982 | Methods useful in the treatment of bone resorption diseases The invention relates to a combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor, said preparation being adapted for (a) the administration of parathyroid hormone during a period of approximately 6 to 24 months; (b) after... | 03/28/2006 |
| 6932962 | Aerosol drug formulations containing hydrofluoroalkanes and alkyl saccharides Aerosol formulations suitable for use in pressurised metered dose inhalers comprise a hydrofluoroalkane propellant, an medicament for inhalation and a surfactant which is a a C8–C16 fatty acid or salt thereof, a bile salt, a phospholipid, or ... | 08/23/2005 |
| 6867181 | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides A method of spherifying a sustained release ionic conjugate which contains a free carboxyl group-containing polymer and a free amino group-containing drug which are ionically bonded to each other. ... | 03/15/2005 |
| 6770625 | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith Pharmaceutical compositions that include a drug-oligomer conjugate, a fatty acid component, and a bile salt component are described. The drug is covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component are present in a weight-... | 08/03/2004 |
| 6770292 | Pharmaceutical compositions for oral administration A method for oral administration of an active principle includes the steps of incorporating an active principle in multilamellar vesicles having a diameter of between 0.1 and 25 μm, and a lamellar liquid-crystal internal structure formed, from the center to the per... | 08/03/2004 |
| 6605591 | Treatment of subnormal bone mineral density A method of treating an individual to increase the individual's bone mineral density (BMD) is disclosed. The method includes co-administering a calcitonin-like agent and a DHEA-like agent. Also disclosed are methods for potentiating the effect of treatmen... | 08/12/2003 |
| 6436367 | Aerosol formulations for buccal and pulmonary application A mixed micellar aerosol pharmaceutical formulation includes a micellar proteinic pharmaceutical agent, an alkali metal lauryl sulphate, at least three micelle forming compounds, a phenol and a propellant. The micelle forming compounds are selected from t... | 08/20/2002 |
| 6423334 | Composition and method for enhancing transport across gastrointestinal tract cell layers A composition for enteral administration having a non-ionic vegetable oil GIT absorption enhancer capable of increasing the enteral absorbability of drugs, especially oral absorbability of hydrophilic and macromolecular drugs. The non-ionic vegetable oil ... | 07/23/2002 |
| 6228836 | Permucous preparation A composition for permucosal administration characterized by containing Antago-3 or a physiologically acceptable salt thereof, and a sucrose fatty acid ester. With the composition for permucosal administration of the invention there is provided a long-ter... | 05/08/2001 |
| 6221958 | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides Disclosed is a sustained release pharmaceutical composition. The composition includes a polyester containing a free COOH group ionically conjugated with a bioactive polypeptide comprising at least one effective ionogenic amine, wherein at least 50% by wei... | 04/24/2001 |
| 6174857 | Composition and method for the treatment of osteoporosis in mammals Pharmaceutical compositions and methods for the treatment of osteoporosis in mammals are disclosed. The compositions are suitable for parenteral administration and comprise Insulin-Like Growth Factor I (IGF-I) and a pharmaceutically acceptable carrier. Th... | 01/16/2001 |
| 6086918 | Oral peptide pharmaceutical products Bioavailability of peptide active agents to be administered orally is enhanced by a pharmaceutical composition providing targeted release of the peptide to the intestine by virtue of an acid-resistant protective vehicle which transports components of the ... | 07/11/2000 |
| 6034175 | Salts of peptides with carboxy-terminated polyesters This invention relates to novel salts composed of a cation derived from a peptide containing at least one basic group and an anion derived from a carboxy-terminated polyester, processes for the manufacture of such salts, and the use of such salts in the m... | 03/07/2000 |
| 5976569 | Diketopiperazine-based delivery systems Compositions useful in the delivery of active agents are provided. These delivery compositions include (a) an active agent; and either (b)(1) a carrier of (i) at least one amino acid and (ii) at least one diketopiperazine or (b)(2) at least one mono-N-sub... | 11/02/1999 |
| 5948825 | Microemulsion preparation containing a slightly absorbable substance Microemulsion preparation in which a plurality of specified surfactants are combined such that aqueous-phase droplets that contain a physiologically active substance of low absorption and which have an average size of 0.4-100 nm are dispersed in an oil-ph... | 09/07/1999 |
| 5948766 | Use of tasteless, hydrolyzed collagen and agent containing the same Tasteless, hydrolyzed collagen from gelatin, gelatin or animal collagenic connective tissue having an average molecular weight of from 1 to 40 kD for the preparation of agents for the treatment of osteoporosis. It may be combined with conventional agents ... | 09/07/1999 |
| 5889110 | Salts of peptides with carboxy-terminated polyesters This invention relates to novel salts composed of a cation derived from a peptide containing at least one basic group and an anion derived from a carboxy-terminated polyester, processes for the manufacture of such salts, and the use of such salts in the m... | 03/30/1999 |
| 5863985 | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides Disclosed is a sustained release pharmaceutical composition. The composition includes a polyester containing a free COOH group ionically conjugated with a bioactive polypeptide comprising at least one effective ionogenic amine, wherein at least 50% by wei... | 01/26/1999 |
| 5776886 | Intravaginal preparation containing physiologically active peptide The present invention relates to an improved intravaginal preparation containing a physiologically active peptide, which comprises a physiologically active peptide, a sucrose fatty acid ester and an organic acid with a pharmaceutically acceptable carrier ... | 07/07/1998 |
| 5759565 | Galenic compositions comprising calcitonin and their use Pharmaceutical compositions for nasal administration comprising i) a calcitonin, and ii) benzalkonium chloride, and/or iv) a surfactant, suitable for application to the nasal mucosa, in iii) a liquid diluent or carrier, suitable for application to the nas... | 06/02/1998 |
| 5733569 | Galenic compositions comprising calcitonin and their use Pharmaceutical compositions for nasal administration comprising i) a calcitonin, and ii) benzalkonium chloride, and/or iv) a surfactant, suitable for application to the nasal mucosa, in iii) a liquid diluent or carrier, suitable for application to the nas... | 03/31/1998 |
| 5719122 | Pharmaceutical compositions containing a calcitonin Pharmaceutical compositions comprising a calcitonin and a polyglycolysed glyceride and a method of enhancing the transdermal or transmucosal absorption of calcitonin in a mammal are disclosed.... | 02/17/1998 |
| 5693338 | Diketopiperazine-based delivery systems Compositions useful in the delivery of active agents are provided. These delivery compositions include (a) an active agent; and either (b)(1) a carrier of (i) at least one amino acid and (ii) at least one diketopiperazine or (b)(2) at least one mono-N-sub... | 12/02/1997 |
| 5674531 | Nanoparticles containing an active substance and a ketalized polytartramidic acid, process for their preparation, and use thereof Nanoparticles containing an active substance and a ketalized polytartramidic acid, process for their preparation, and use thereof. Nanoparticles containing an active substance and a ketalized polytartramidic acid are suitable as vehicles for active substa... | 10/07/1997 |
| 5672659 | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides A composition including a polyester containing one or more free COOH groups ionically conjugated with a bioactive polypeptide comprising at least one effective ionogenic amine, wherein the polyester contains a member selected from the group of L-lactic ac... | 09/30/1997 |
| 5637309 | Physiologically active substance-prolonged releasing-type pharmaceutical preparation A prolonged releasing pharmaceutical preparation is provided carrying a physiologically active substance, particularly, calcitonin gene-related peptide (CGRP) or a maxadilan (MAX). This pharmaceutical preparation can attain the expected effects by incorpo... | 06/10/1997 |
| 5514365 | Pharmaceutical compositions comprising calcitonin for intranasal administration A method for treating a patient suffering from any of osteoporosis, Paget's disease and hypercalcemia by intranasally administering to said patient by spray a calcitonin solution consisting of calcitonin dissolved in a 0.9% aqueous sodium chloride solutio... | 05/07/1996 |
| 5500224 | Pharmaceutical compositions containing nanocapsules A pharmaceutical composition in the form of a colloidal suspension of nanocapsules, comprising an oily phase consisting essentially of an oil containing dissolved therein a surfactant and suspended therein a plurality of nanocapsules having a diameter of ... | 03/19/1996 |
| 5439688 | Process for preparing a pharmaceutical composition A pharmaceutical composition is prepared in the form of microparticles or of an implant comprising a biodegradable polymer selected from poly-1,4-butylene succinate, poly-2,3-butylene succinate, poly-1,4-butylene fumarate and poly-2,3-butylene succinate, ... | 08/08/1995 |
| 5310727 | Pharmaceutical compositions for parenteral use containing a calcitonin as the active ingredient A freeze-dried pharmaceutical composition for parenteral administration which includes a therapeutically effective amount of a calcitonin, as the active ingredient, and human albumin. The injectable solution which is obtained by dissolving the freeze-dried ... | 05/10/1994 |
| 5283064 | Large intestinal dissociative hard capsules A large intestinal dissociative hard capsule comprising a capsule mainly composed of chitosan, the viscosity at 20° C. of a solution obtained by dissolving the chitosan in an aqueous 1% by weight acetic acid solution being not higher than 100 cps and the... | 02/01/1994 |
| 5281580 | Calcitonin-containing emulsion for nasal administration The present invention is to provide emulsion preparations for nasal administration containing calcitonins, which are safely and effectively administrated compared with the conventional calcitonin preparations. The emulsions are prepared by using a calcito... | 01/25/1994 |
| 5279836 | Topical use of calcitonin for the preparation of medications in senile idiopathic cataract and a pharmaeutical composition thereof A new use of calcitonin, as an active principle, is provided for the preparation of topically appliable medications in the treatment of pre-senile and senile idiopathic cataract; and a pharmaceutical composition containing elcatonin as active principle fo... | 01/18/1994 |
| 5225205 | Pharmaceutical composition in the form of microparticles A method for preparing a pharmaceutical composition in the form of microparticles, the composition thus obtained and its use for preparing injectable suspensions.... | 07/06/1993 |
| 5149537 | Use of taurocholic acid and its salts as enhancers for calcitonin containing pharmaceutical compositions Suppositories comprising a suppository base, a calcitonin and taurocholic acid or a pharmaceutically acceptable salt thereof exhibit improved bioavailability and are well tolerated.... | 09/22/1992 |
| 5124315 | Liquid pharmaceutical composition for nasal administration containing a polypeptide as active ingredient A liquid composition for nasal administration of polypeptide/s containing ammonium tartrate and a buffer together with optional adiuvants.... | 06/23/1992 |
| 5011678 | Composition and method for administration of pharmaceutically active substances Pharmaceutically active substances are administered in aerosol form by applying to a mucosal surface of the body a composition comprising a medically effective amount of a pharmaceutically active substance, a biocompatible amphiphilac steroid and a bicomp... | 04/30/1991 |
| 4994439 | Transmembrane formulations for drug administration Compositions for the administration of protein or peptide drugs across membranes show low toxicity and efficient permeation when the medium is a mixture of a bile salt or fusidate with a nonionic detergent. Various specific compositions are exemplified.... | 02/19/1991 |
| 4988512 | Nasal pharmaceutical compositions Solid nasal inserts of calcitonin and other peptides have particularly interesting drug absorption profiles.... | 01/29/1991 |
| 4977139 | Aqueous elcatonin solution composition The present invention provides an aqueous solution composition containing elcatonin as an active ingredient used for hypercalcemia or bone Paget's disease or improvement of pain in osteoporosis, etc. and which is highly stable against shaking, light and h... | 12/11/1990 |
